Protagenic
PTIX

From June 30, 2025 to September 30, 2025 Rounding from reverse split Shares issued for warrant exercises

From March 31, 2025 to June 30, 2025 Issuance of Series A Convertible Preferred Stock to officers Adjustment of shares in reverse merger Shares issued in connection with Phytanix Bio purchase Shares issued for cash Shares issued for warrant exercises Rounding from reverse split

a 1-for-14 reverse stock split of the Company's issued and outstanding common stock

From December 31, 2023 to December 31, 2024 Stock issued for cash Stock and warrants issued at offering

From June 30, 2024 to September 30, 2024 Stock issued for cash

From March 31, 2024 to June 30, 2024 Stock issued for cash

From December 31,2022 to December 31,2023 Conversion of notes and interest Rounding from reverse split

From December 31, 2022 to March 31, 2023 Rounding from reverse split

Protagenic Therapeutics, Inc. today announced that the Company’s Board of Directors has approved a 1-for-4 reverse stock split of the Company’s issued and outstanding common stock.

From March 31, 2022 to June 30, 2022 Conversion of notes and interest

From December 31, 2021 to March 31, 2022 Conversion of notes and interest

From December 31, 2020 to December 31, 2021 Exercise of options Exercise of warrants Issuance of shares and warrants from offering, net of offering costs Conversion of preferred stock Conversion of notes and interest Stock issued for underwriter

From June 30, 2021 to September 30, 2021 Conversion of preferred stock Conversion of notes and interest Shares issued to underwriter as stock issuance costs

From March 31, 2021 to June 30, 2021 Issuance of shares and warrants from offering, net of offering costs Exercise of options Exercise of warrants Conversion of preferred stock Conversion of notes and interest

1.Securities offered by the Company 3,180,000 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock, for a total of 3,180,000 shares and 3,180,000 warrants to purchase up to an aggregate of 3,180,000 shares of common stock 2.The number of shares of common stock to be outstanding immediately after the consummation of this offering is based on shares of common stock outstanding as of April 15, 2021, which does not reflect the potential issuance of up to 1,255,000 shares of common stock upon the exercise of outstanding stock options under 2006 Equity Compensation Plans and up to 4,342,861 shares of common stock upon the exercise of outstanding stock options under 2016 Equity Compensation Plan

From December 31, 2020 To March 31, 2021 Exercise of options Exercise of warrants

On July 27, 2016 we effectuated a 1-for-15,463.7183 Reverse Split which will trigger the automatic conversion of our Series B Preferred Stock into our common stock. As a result of the Reverse Split, each share of our Series B Preferred Stock will convert into approximately one share of our common stock. Upon the effectiveness of the Reverse Split, the 11,018,766 outstanding shares of our Series B Preferred Stock will immediately and automatically convert into 11,018,766 shares of our common stock (accounting for the Reverse Split ratio).

from January 1, 2011 to September 30, 2011 Issuance of common stock

from January 1, 2011 to June 30, 2011 Stock based compensation expense

Stock based compensation expense

Stock based compensation expense Issuance of common stock Common stock issued in connection with an asset purchase On December 2, 2010, we effected a 1-for-4 reverse stock split of our common stock.

a 1-for-4 reverse stock split of its common stock

from December 31, 2008 to December 31, 2009 Stock based compensation expense Issuance of common stock Common stock issued in connection with a business combination Purchase of common stock, at cost